Top 10 Major Players in the South Korea Ataxia Market | Top Companies & Insights 2026

Top 10 Major Players in the South Korea Ataxia Market

The South Korea Ataxia market is shaped by prominent local players and established global pharmaceutical companies, each vying for a high market share through innovative treatment development and strong regional presence. Key players include GC Biopharma (GC Pharma), Hanmi Pharmaceutical Co., Ltd., Celltrion, Inc., Yuhan Corporation, and Daewoong Pharmaceutical Co., Ltd.

South Korea Ataxia Market Overview

According to 6Wresearch, the South Korea Ataxia market is set for expansion, due to increasing awareness levels and the prevalence of neurodegenerative disorders within its rapidly aging population. Ataxia is a disorder that affects motor functions, and is being recognized for its impact on quality of life.

The market is accelerated by the need to develop effective treatments, along with increasing focus on neurological health. The rise of healthcare infrastructure in South Korea, is driving the growth of this market, with initiatives being implemented to develop special treatments for such disorders. Additionally, Organizations are investing heavily in R&D to cater to the needs of individuals suffering from Ataxia.

Competitive Landscape

The competitive landscape of the South Korea Ataxia Industry is characterized by global pharmaceutical companies and highly sophisticated local firms that use their superior R&D capabilities to bring innovations in the treatment of neurodegenerative disorders. The dominant leaders are currently focused on expanding their footprint by forging strategic partnerships and conducting large-scale clinical trials.

Below is a list of leading players operating in the South Korea Ataxia Market:

1. GC Biopharma (GC Pharma)

GC Biopharma is a dominant force, providing plasma protein therapies and researching rare disease treatments relevant to Ataxia.

2. SK Biopharmaceuticals

SK Biopharmaceuticals maintains a strong presence, focusing on Central Nervous System disorders and specialized therapies for movement and seizure disorders.

3. Celltrion, Inc.

Celltrion is a key player, utilizing its expertise in biologics and biosimilars to expand treatment options for rare neurological and autoimmune conditions.

4. Hanmi Pharmaceutical Co., Ltd.

Hanmi Pharmaceutical focuses on the development of novel drugs, targeting metabolic and rare neurodegenerative diseases.

5. Yuhan Corporation

Yuhan is a leading domestic producer, offering a wide range of CNS medications and maintaining strategic partnerships with global leaders.

6. Daewoong Pharmaceutical Co., Ltd.

Daewoong contributes to the market through its expertise in prescription drugs and R&D into cell and gene therapies.

7. Samjin Pharm Co., Ltd.

Samjin remains a significant provider of neurological and supportive treatments, particularly in the management of secondary symptoms of motor disorders.

8. Sanofi (South Korea)

Sanofi is a major manufacturer that produces advanced treatments for rare genetic diseases, including orphan drugs for hereditary Ataxia.

9. Novartis Korea

Novartis is an industry pioneer in neuroscience, focusing on therapies for complex neurodegenerative conditions through molecular innovation.

10. Viatris Korea

Viatris provides a diverse portfolio of established medicines used in long-term symptom management and patient care.

Top 10 Major Players in the South Korea Ataxia Market: FAQs